Influenza is fiercer than SARS, and the anti influenza market is like a roller coaster

After entering the new century, with the SARS epidemic caused by the coronavirus, as well as the H5N1 avian influenza virus and a H1N1 influenza virus, it has brought great harm to human beings People have begun to pay more attention to anti viral drugs The rise of influenza virus has also attracted more attention from the capital market in the industry On August 3, 2017, the Hong Kong Department of health released a news report that from May 5 to August 2, in less than three months, 14713 people were diagnosed with influenza, 450 of them suffered from severe influenza and 307 died The death rate is as high as 2.1% It is reported that the number of deaths caused by this influenza is even more than that directly caused by SARS virus in 2003 The Hong Kong Department of Health reported that the peak influenza positive rate in Hong Kong this summer reached 40.86%, exceeding the peak of 38.71% since the winter of 2015 It is mainly influenza A H3N2, accounting for 88.8% Influenza A H3N2 is usually high in the elderly population The flu crisis has spread to Shenzhen, a bridge from Hong Kong Shenzhen has the highest level of influenza warning for three consecutive weeks, and this week is still in the "dangerous period" According to the surveillance data of Shenzhen influenza surveillance outpost hospital, the influenza index is grade I, indicating that the influenza epidemic is of high intensity and easy to occur, and it is still the best policy to take active prevention After entering the new century, with the SARS epidemic caused by the coronavirus, as well as the H5N1 avian influenza virus and a H1N1 influenza virus, it has brought great harm to human beings People have begun to pay more attention to anti viral drugs The rise of influenza virus has also attracted more attention of the capital market in the industry   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); Box sizing: border box! Im portant; word wrap: break word! Im portant; "> influenza virus infection should not be underestimated According to the data released by the World Health Organization, there are 600-1.2 billion influenza cases every year in the world, including 3-5 million severe influenza cases and 250000-500000 deaths every year In recent years, influenza A (H1N1), a (H3N2) and B (influenza B) have spread around the world, as well as h7n9 avian influenza and H5N1 and h5n8 highly pathogenic avian influenza viruses in South Korea, all of which threaten the normal life of human beings Over the years, the harm of seasonal influenza is more serious, especially for the elderly, children and patients with chronic basic diseases In the season of influenza epidemic, it is very effective to control the influenza epidemic by taking comprehensive measures, mainly vaccination In clinical treatment, anti influenza drugs play an important role However, the emergence of anti influenza drugs is relatively late, and there are relatively few clinically effective and effective treatment drugs, which are only small varieties of anti infective drugs Driven by the spread of the epidemic and market demand, the global anti influenza drugs have reached a new peak   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> the anti influenza market is like a roller coaster At present, the global anti influenza drugs are mainly Tamiflu from Roche, Switzerland, abidol from OJSC, Relenza from GlaxoSmithKline, UK and laninamivir from Japan The domestic and foreign markets have been basically in line with each other Antiviral drugs play a very important role in dealing with highly pathogenic and highly variable viruses According to the data of China's hospital monitoring and analysis system for proprietary Chinese medicine and chemical medicine (HDM) on minenet, in 2016, the market of anti influenza virus and influenza vaccine in public hospitals in key cities in China was 80 million yuan, an increase of 65.67% over the previous year, and anti influenza drugs accounted for nearly 98% of the absolute share Domestic anti influenza drugs mainly include oseltamivir, paramivir, abidor, zanamivir and rimantadine, involving 16 enterprises holding the registration number of anti influenza virus preparations The proportion of influenza vaccine market is small, and the self paid vaccine shows a downward trend Ostavitspeed Oseltamivir (oseltamivir) is a specific inhibitor of neuraminidase, which can inhibit the mature influenza virus from leaving the host cells, thus inhibiting the spread of influenza virus in the human body It is the most effective antiviral drug for the treatment of influenza A and B, which can control the course of influenza earlier, alleviate the high fever symptoms of patients, and prevent influenza virus and avian influenza virus Harm to human cells and tissues In 1996, oseltamivir was R & D and listed by Gilead company and jointly developed and operated by Roche company after being transferred In 2001, oseltamivir entered China under the trade name of Tamiflu In 2005, the U.S FDA approved oseltamivir as a drug to prevent influenza in children The product has been sold in many countries around the world and is an important type of influenza prevention reserve Due to its close relationship with the epidemic, the sales market of oseltamivir fluctuated greatly In 2016, Roche's Tamiflu sales reached CHF 7.94, with an increase rate of 12.62% So far, CFDA has approved the production of oseltamivir phosphate by Roche, Shanghai Roche pharmaceutical, Shanghai Sino Western 3D pharmaceutical and Yichang dongyangguang Changjiang pharmaceutical, laying a solid foundation for the prevention and treatment of influenza outbreaks in China According to HDM system data, in 2016, the amount of oseltamivir used in public hospitals in key cities in China was 72.32 million yuan, an increase of 105.22% over the previous year, accounting for 92.41% of influenza drugs According to the enterprise competition of oseltamivir, Kewei of Yichang dongyangguang Changjiang Pharmaceutical Co., Ltd accounted for 79.98%, Tamiflu of Roche accounted for 19.64%, and ORFI of Shanghai Sino Western 3D Pharmaceutical Co., Ltd accounted for 0.38% Covey shows a trend of increasing year by year, and the performance of Duffy and ORFI is relatively poor In addition to oseltamivir, rimantadine, zanamivir and abidor are relatively stable in the emerging anti influenza virus, while palamivir will be the rising star On April 5, 2013, CFDA approved the launch of the first class new anti influenza drug, peramivir injection, which is independently developed in China It is another new type of influenza virus NA inhibitor after the successful launch of zanamivir and oseltamivir According to the data of HDM system, in 2016, the market of public hospitals in key cities in China was 3.54 million yuan, an increase of 500% over the previous year Guangzhou Nanxin Pharmaceutical Co., Ltd has been approved to produce the exclusive domestic product of paramimivir injection, which is a new type of anti influenza virus drug The antipyretic time of paramimivir to influenza A and B viruses is the fastest drug among the neuraminidase inhibitors so far, and its human bioavailability is more than 98% In the face of the increasing frequency of influenza virus infection, palamivir injection provides patients with new treatment options It is worth mentioning that zanamivir is a sialic acid inhibitor of influenza virus By inhibiting the neuraminidase of influenza virus, zanamivir can change the aggregation and release of influenza virus in infected cells and is used to treat influenza caused by influenza A virus In September 2006, GlaxoSmithKline Pharmaceutical Co., Ltd of the United Kingdom authorized China Xiansheng pharmaceutical to develop and produce zanamivir, and also authorized Xiansheng pharmaceutical to sell zanamivir in China, Indonesia, Thailand, Vietnam and other 50 developing countries and regions In July 2009, GlaxoSmithKline (Australia / France) introduced the new drug, zanamivir powder for inhalation, into the Chinese market, under the trade name of "elovir", and has entered the hospital market In February 2010, CFDA approved Nanjing xianshengdongyuan Pharmaceutical Co., Ltd to produce zanamivir API and / or inhaled powder mist, but the performance of the product after its launch was short of ups and downs With the rapid development of medical technology, people's understanding of influenza virus is gradually improving Under the influence of multiple factors such as the variability of influenza virus antigen and acute respiratory virus infection, it is obviously difficult to rely on prevention alone, and antiviral treatment is still one of the main treatment options Many countries around the world have also successively carried out strategic reserve of anti influenza drugs As the best plan to resist the sudden outbreak of influenza, it objectively promoted the rapid development of anti influenza drug market.